Transgenic Mouse

转基因小鼠/ES细胞共享资源自1993年以来一直存在，自1995年范德比尔特-英格拉姆癌症中心（VICC）获得第一笔癌症中心支持赠款以来，一直获得NCI的持续资助。在上一次竞争性续订时，此共享资源获得了“优秀”评级。该资源提供基因靶向、DNA原核显微注射、ES细胞显微注射、辅助生殖以及精子和胚胎冷冻保存服务， VICC的成员。这些服务对于生殖系改变小鼠的生成、维护和长期储存至关重要。该资源继续以多学科方式运作，自上次竞争性评价以来发生了几次重大变化，使其能够继续以合理的价格提供基因靶向和显微注射服务，开发几项新服务，并改进其质量控制和数据管理战略。转基因小鼠/胚胎干细胞共享资源继续提供服务，仍然在高需求和至关重要的新一代 癌症和其他疾病的小鼠模型。这将是至关重要的，因为来自全基因组癌症研究的基因特异性信息被转化为人类癌症的小鼠模型。此外，该资源支持的技术基础预计将在允许范德比尔特研究人员在未来适应人类多能干细胞的使用方面发挥重要作用。

The Transgenic Mouse/ES Cell Shared Resource has been in existence since 1993 and has received continuous funding from the NCI since the Vanderbilt-lngram Cancer Center (VICC) was awarded its first Cancer Center Support Grant in 1995. At the time of the last competitive renewal, this shared resource received an "Outstanding" rating. This resource provides gene targeting, DNA pronuclear microinjections, ES cell microinjections, assisted reproduction and both sperm and embryo cryopreservation services to members of the VICC. These services are essential for the generation, maintenance, and long-term storage of germline-altered mice. The resource continues to function in a multidisciplinary manner and has undergone several significant changes since the last competitive evaluation that have enabled it to continue to provide gene targeting and microinjection services at reasonable prices, to develop several new services, and to improve both its quality control and data management strategies. The Transgenic Mouse/ES Cell Shared Resource continues to offer services that remain in high demand and vital to the generation of new mouse models of cancer and other diseases. This will be critical as the gene-specific information from genome-wide cancer studies is translated to mouse models of human cancer. Moreover, the technology base that this resource supports is expected to be important in allowing Vanderbilt investigators to adapt to using of human pluripotent stem cells in the future.